Search Results

Biophytis SA will hold its Combined General Meeting on June 24, 2024 at 2pm at Sorbonne Université - Amphi Herpin - 4 Place Jussieu, 75005 Paris.

Excision BioTherapeutics, Inc. today announced that it will make an oral presentation on April 24, 2024, at CRISPRMED24, the first CRISPR Medicine Conference, which is being held from April 23-25 in Copenhagen, Denmark.

Global DNA Nanotechnology Market is valued at US$ 4.34 Bn in 2023, and it is expected to reach US$ 24.29 Bn by 2031, with a CAGR of 24.67% during the forecast period of 2024-2031.

Chemomab Therapeutics Ltd. today announced a new scientific publication that further confirms the important role of the soluble protein CCL24 in the pathologies underlying the rare fibrotic liver disease primary sclerosing cholangitis (PSC).

Excision BioTherapeutics, Inc. today announced that it will deliver an oral presentation highlighting new data from its herpes simplex virus-1 keratitis (HSV-1 Keratitis) program, EBT-104, at CRISPRMED24, the CRISPR Medicine Conference, which is being held from April 23-25 in Copenhagen, Denmark.

Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, is scheduled to present at the CJS Securities 24th Annual New Ideas Summer Conference on Wednesday, July 10, 2024, in White Plains, New York.

Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Oppenheimer 24th Annual Consumer Growth & E-Commerce Conference, being conducted virtually on Tuesday, June 11th at 1:30 PM EDT.

Calidi Biotherapeutics Inc. is pleased to invite investors to a webinar on April 24, 2024 at 4:15 p.m. ET.

Cordis, a global leader in the development and manufacturing of interventional cardiovascular and endovascular technology, today announces positive 24-month results from the SELUTION SFA Japan Trial.

Pheast Therapeutics today announced the first presentation of preclinical data for PHST001, an anti-CD24 antibody drug candidate that is designed to block a key macrophage “don’t eat me” signal on cancer cells.